Bio & Pharma
S. Korea's SillaJen launches clinical trials in US for new anti-cancer drug
The biotech company will adopt a candidate substance from a Swiss pharmaceutical company
By Dec 14, 2022 (Gmt+09:00)
1
Min read
Most Read
South Korea’s Rznomics inks $1.3 bn out-licensing deal with Eli Lilly


In China’s waterway city Hangzhou, K-beauty redefines ‘shuiguang'


When in S. Korea, it’s a ritual: Foreigners make stops at CU, GS25, 7-Eleven


Kumho Tire shuts Gwangju plant after fire, derailing record sales run


Korea’s aesthetic medicine enjoys golden era with surge in foreign spending



South Korean biotech company Sillajen Inc. has started recruiting patients for Phase 1 clinical trials in the US for an anti-cancer drug from a Swiss pharmaceutical company.
SillaJen plans to expedite clinical development and promote technology transfer.
SillaJen CEO Kim Jae-kyung on Tuesday told a news conference at Korea Press Center in Seoul, "Three clinical institutions in the US this month will start recruiting patients for Phase 1 clinical trials of BAL0891," adding, "We will quickly conduct Phase 1 to fill the unmet demand for new anti-cancer drugs."
The company plans to hold clinical trials for intractable carcinomas such as those of triple-negative breast cancer and expand indications to other carcinomas such as those of blood cancer. BAL0891, a candidate substance for suppressing mitotic checkpoints, was introduced by SillaJen from Basilia Pharmaceutica International of Switzerland; the Korean company also has an exclusive license for use of the substance.
Preclinical studies have shown that BAL0891 effectively inhibits an array of cancer cells including those of triple-negative breast, endometrial, colorectal, urothelial, gastric and kidney cancer. Intravenous administration of the drug instead of oral also proved more effective against cancer.
Write to Jae-Young Han at jyhan@hankyung.com
More to Read
-
-
-
Bio & PharmaS.Korea’s Lunit installs breast cancer AI diagnostic tool at 200 US hospitals
May 20, 2025 (Gmt+09:00)
-
-
Comment 0
LOG IN